Cingulate (CING) Change in Receivables (2021 - 2024)
Cingulate's (CING) quarterly Change in Receivables came in at -$12375.0 in Q1 2024, up 93.89% YoY from -$6382.5 in Q2 2023, and down 240.85% on a QoQ basis from $8786.0 in Q4 2023.
Cingulate (CING) Change in Receivables (2021 - 2024) Analysis & Trends
Cingulate (CING) has 4 years of Change in Receivables data on file, last reported at -$12375.0 in Q1 2024.
- Quarterly Change in Receivables rose 93.89% year-over-year to -$12375.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$29706.0 (up 95.2% YoY) and the FY2025 annual result came in at -$18312.0, down 256.47% from the prior year.
- Change in Receivables slipped to -$12375.0 in Q1 2024, from $8786.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $333186.0 in Q4 2021 to a low of -$511258.0 in Q2 2022.
- A 4-year average of -$11501.9 and a median of $3517.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables tumbled 787.17% — and 2023, when it jumped 100.69%.
- Tracing CING's Change in Receivables over 4 years: stood at $333186.0 in 2021, then sank by 43.85% to $187083.0 in 2022, then plunged by 95.3% to $8786.0 in 2023, then sank by 240.85% to -$12375.0 in 2024.
- The last three Change in Receivables figures came in at -$12375.0 (Q1 2024), $8786.0 (Q4 2023), and -$29634.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -12,375.00 |
| Mar 31, 2024 | -12,375.00 |
| Dec 31, 2023 | 8,786.00 |
| Dec 31, 2023 | 8,786.00 |
| Sep 30, 2023 | -29,634.00 |
| Sep 30, 2023 | -29,634.00 |
| Jun 30, 2023 | 3,517.00 |
| Jun 30, 2023 | 3,517.00 |
| Mar 31, 2023 | -202,479.00 |
| Mar 31, 2023 | -202,479.00 |
| Dec 31, 2022 | 187,083.00 |
| Dec 31, 2022 | 187,083.00 |
| Sep 30, 2022 | -92,764.00 |
| Sep 30, 2022 | -92,764.00 |
| Jun 30, 2022 | -511,258.00 |
| Jun 30, 2022 | -511,258.00 |
| Mar 31, 2022 | -38,877.00 |
| Mar 31, 2022 | -38,877.00 |
| Dec 31, 2021 | 333,186.00 |
| Dec 31, 2021 | 333,186.00 |